title: Relevant incidence of cervical arthritis in patients with erosive seropositive rheumatoid arthritis even today.
abstract: OBJECTIVE
  This paper aims to investigate adherence to, and outcome of, radiographic screening of patients with rheumatoid arthritis (RA) for cervical involvement, given the availability of state of the art disease-modifying anti-rheumatic drug (DMARD) and biological therapies.
  
  
  METHODS
  Cervical screening results and clinical information were obtained from the charts of 395 consecutive patients with rheumatoid arthritis who attended an academic rheumatology outpatient clinic in a 3-month interval. This sample was combined with eight patients who underwent C1-C2 fusion at the Department of Orthopaedic Surgery.
  
  
  RESULTS
  Reports on cervical spine x-ray films were not found in the charts of 67 patients (17 %), including 21 (8 %) of the 257 patients with a disease duration of ≥5 years. Nevertheless, 17 (7%) of these 257 patients had an increased atlantodental distance. An additional 4 RA patients of the Department of Orthopaedics were added for a total of 21 patients with cervical arthritis, 13 of whom had no cervical symptoms. All 21 patients with cervical arthritis had erosive peripheral arthritis with at least 10 years of disease duration, and were positive for rheumatoid factor. Almost half of these patients were not under adequate DMARD therapy when cervical instability was diagnosed, and none were on biological response modifiers.
  
  
  CONCLUSIONS
  Screening for cervical arthritis is still of importance, especially in patients with erosive seropositive disease. In view of the documented incidence, adherence to screening protocols was disappointing.
authors.affiliation: Department of Medicine III, Technical University of Dresden, Germany. ariane.hagenow@googlemail.com
authors.forename: Ariane
authors.initials: A
authors.lastname: Hagenow
authors.forename: Jens
authors.initials: J
authors.lastname: Seifert
authors.forename: Astrid
authors.initials: A
authors.lastname: Zeissig
authors.forename: Karsten
authors.initials: K
authors.lastname: Conrad
authors.forename: Alexander
authors.initials: A
authors.lastname: Kleymann
authors.forename: Martin
authors.initials: M
authors.lastname: Aringer
mesh_terms: D000046:Academic Medical Centers; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000453:epidemiology; D001688:Biological Products / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002574:Cervical Vertebrae / Q000000981:diagnostic imaging* / Q000187:drug effects; D016009:Chi-Square Distribution; D005260:Female; D005858:Germany / Q000453:epidemiology; D017408:Guidelines as Topic; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011237:Predictive Value of Tests; D015995:Prevalence; D011379:Prognosis; D011859:Radiography; D012217:Rheumatoid Factor / Q000097:blood*; D018570:Risk Assessment; D012307:Risk Factors; D025241:Spondylarthritis / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000453:epidemiology; D013997:Time Factors; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products; D015415:Biomarkers; D012217:Rheumatoid Factor